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Hospital, 3) Zhejiang Chinese Medicinal University and 4) Department of Internal Medicine, Hangzhou Xixi Hospital, Hangzhou, Zhejiang, ChinaAbstractThe high rate of relapse after cessation of nucleos(t)ide analogues (NUCs) treatment in chronic hepatitis B (CHB) patients leads us to reassess
the feasibility for off-therapy, but long-term follow-up data are scarce. We assessed the feasibility for off-therapy by a long-term observation
of relapse in response to lamivudine (LAM) and telbivudine (LdT). Eighty-six NUC-naive CHB patients, treated with LAM (n = 46) or LdT
(n = 40) who reached the guidelines recommended for off-therapy, were followed for up to 10 years. Hepatitis B virus (HBV), viral serology
and biochemistries were periodically determined. COX model was used to predict the risk of relapse. A total of 52.3% of patients
experienced relapse within a median of 115 months (range, 61–122 months). A total of 93.3% of relapses occurred within 48 months.
Relapse rates in hepatitis B e antigen (HBeAg)-positive (n = 56) and HBeAg-negative (n = 30) patients were 39.3% and 76.7%,
respectively (p < 0.01). HBeAg-positive patients who achieved an early viral response (EVR), deﬁned as undetectable HBV DNA within 6
months, had a lower relapse rate compared to non-EVR patients (21.4% vs. 59.2%, p < 0.01). EVR patients who had both lower HBV
DNA (<106 copies/mL) at baseline and lower hepatitis B surface antigen (HBsAg) at end of treatment had a relapse rate of 10.7%. The
high relapse rates in CHB patients over this 10-year follow-up make LAM or LdT off therapy infeasible in most of the cases, except in
the case of HBsAg loss and/or seroconversion. HBeAg-positive patients with EVR, lower HBV DNA and HBsAg had lower relapse rates
and could be good candidates for off-therapy. Long-term monitoring, especially during the ﬁrst 4 years, is critical for patients off-therapy.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
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Keywords: Chronic hepatitis B, long-term durability, nucleoside analogues
Original Submission: 16 April 2015; Revised Submission: 4 July 2015; Accepted: 24 July 2015
Editor: G. Antonelli
Article published online: 4 August 2015Data in this study were partially presented at the AALSD 65th annual
meeting, 7–11 November 2014, Boston, Massachusetts, USA.
Corresponding author: H.-Y. Pan, Department of Infectious
Diseases, Zhejiang Provincial People’s Hospital, Zhejiang Chinese
Medicinal University, Hangzhou, Zhejiang, China
E-mail: panhongying@sohu.comIntroductionHepatitis B virus (HBV) infection poses a signiﬁcant global
health problem, with an estimated 350 to 400 million
chronically infected individuals worldwide. Without effective
treatment, these patients may ultimately progress to moreClinical Microbiology and Infection © 2015 The Authors. Published by El
This is an open access artiadvanced stages of liver diseases, including liver ﬁbrosis,
cirrhosis, hepatocellular carcinoma and other complications
[1–3]. Recent studies have shown that these advanced stages
of liver diseases could be prevented, delayed or even reversed
by effective antiviral therapy [4–6]. Oral antiviral nucleos(t)
ides (NUCs) have long been used as an effective antiviral
therapy in clinical practice, and with the advent of potent and
high genetic barrier agents to NUCs resistance, such as
entecavir (ETV) and tenofovir, more patients have beneﬁted
from antiviral therapy. However, these NUCs cannot
completely eradicate HBV, especially in patients infected early
in life who have HBV integrated into the nucleoli of infected
hepatocytes [7,8]; long-term or indeﬁnite antiviral therapy is
usually recommended.Clin Microbiol Infect 2015; 21: 1123.e1–1123.e9
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1123.e2 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIWhether NUCs treatment can be discontinued for patients
who have had a period of virus suppression with long-term
therapy, particularly in hepatitis B e antigen (HBeAg)-negative
patients, is still debatable. The clinical practice guidelines for
chronic hepatitis B (CHB) management in international soci-
eties have different criteria for off-therapy [1,9,10]. In HBeAg-
positive patients without cirrhosis, the criteria for off-therapy
are HBeAg seroconversion plus undetectable HBV DNA for at
least 6 to 12 months, followed by 6 to 24 months of continuous
consolidation therapy. The criteria for HBeAg-negative patients
are HBsAg loss/seroconversion, which is rarely achieved. In
real-world clinical practice, patients who reached these end
points for off therapy were eventually found to have episodes of
either viral or clinical relapse. Reported relapse rates are as
high as 50% within the ﬁrst year after off-therapy [11–13],
which raises a question regarding the feasibility for off-therapy
and drives clinical researchers to delve into the relevant factors
for relapse. Reported data have shown that age, serum bilirubin,
anti-HBe, consolidation therapy, HBV DNA, alanine amino-
transferase (ALT) and HBsAg may be associated with relapse
[12,14,15]. The results of recent studies evaluating relapse in
HBeAg-negative patients with ETV therapy showed that only
baseline HBV DNA level was associated with relapse [16,17].
However, these studies were done in a variety of populations
and had a different point of view for determining off-therapy
feasibility, as they were a short-term observation with a
follow-up of 1 to 2 years, which prematurely assessed relapse.
In this study, we assessed the relapse rate with long-term
observation; we analysed baseline and on-treatment factors
that might be related to clinical relapse after lamivudine (LAM)
or telbivudine (LdT) off-therapy, both of which have been
clinically practiced for a longer period of time in Chinese CHB
patients; and we aimed to determine feasibility for off-therapy.Materials and MethodsStudy design and patient selection
The study was designed as a retrospective–prospective cohort.
The retrospective study was performed by systematically
reviewing medical records (chart review) in 2010 and before;
the prospective study was carried out continuously since 2010.
The study protocol for human clinical research was approved
by the institutional review board at our institution. Each
enrolled patient for the prospective study provided a signed,
informed, written consent; written consent was waived for the
retrospective study.
A total of 368 NUC-naive CHB patients in our liver clinics
were consecutively treated with LAM (n = 207) and LdT
(n = 161) from January 2000 to November 2010, andClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licesubsequently from November 2010 to June 2014. A total of
261 patients treated with either LAM (n = 163) or LdT (n = 98)
were excluded for the following reasons: (a) continuous ther-
apy (n = 86); (b) switched to or added on another antiviral
agent (n = 42); (c) incomplete medical records (n = 46); (d)
noncompliance with this follow-up study (n = 30); (e) concur-
rence with other liver diseases (n = 44); (f) evidence for hepatic
cirrhosis either with imaging or histology (n = 13). One hun-
dred seven patients who met the criteria for discontinuation of
LAM or LdT in HBeAg-positive (undetectable HBV DNA by
PCR demonstrated on two occasions, 6 months apart, normal
ALT plus HBeAg seroconversion at least 2 years) and HBeAg-
negative (undetectable HBV DNA by PCR demonstrated on
three occasions, 6 months apart, sustained for at least 2.5
years) by Chinese Medical Association (CMA) recommenda-
tions for CHB management [18] were enrolled and completed
this study (Fig. 1). Inclusion criteria were: (a) age >18 years; (b)
serum HBsAg positive for at least 6 months; (c) serum HBV
DNA 1 × 105 copies/mL; (d) serum ALT levels continued or
intermittent increase more than the upper limit of normal
(ULN = 50 IU); (e) total bilirubin <34.2 μmol/L; (f) no NUCs
provided in the past 3 years; (g) duration of consolidation
therapy >24 months; (h) post-treatment follow-up of at least 48
months.
The enrolled patients had been orally administered LAM
100 mg daily or LdT 600 mg daily, reached the indication for
off-therapy, continuous consolidation therapy, and were fol-
lowed up. ALT was monitored monthly in the ﬁrst 3 months
and then at least every 3 months, along with serum HBV DNA
assays every 3 to 6 months during the follow-up period.
Screening ultrasonography and α-fetoprotein assays were per-
formed every 6 months. Early viral response (EVR) is deﬁned as
HBV DNA reaching an undetectable level (<1 × 103 copies/mL)
within 6 months after initiation of therapy. Clinical relapse is
deﬁned as increased serum HBV DNA to >1 × 104 copies/mL
from an undetectable level followed by elevation of ALT greater
than the ULN. HBV DNA and/or ALT were retested for
conﬁrmation and further evaluation if either increased.
Consolidation therapy is deﬁned as continuous treatment after
reaching an indication for off-therapy.
Age, gender, biochemistries and viral markers at baseline, the
end of 3 and 6 months on-treatment and at off-therapy were
compared between patients who experienced relapse and
those with sustained viral responses (SVR) along with treatment
duration and consolidation treatment durations.
The guidelines for off-therapy in CHB patients were un-
available prior to 2005, when the ﬁrst version of the guidelines
was released [18]. Patients were selected retrospectively for
this study based on chart review and intact medical records and
included LAM- or LdT-treated patients who discontinued theirropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
nses/by-nc-nd/4.0/)
FIG. 1. Demographics of study patients. Among 368 NUC-naive CHB patients treated with LAM (n = 207) or LdT (n = 161) in 2010 and after, 261
patients were excluded because they received continuous therapy; switched to or added on another agent; had incomplete MRs; were noncompliant
with the study protocol; had other concurrent liver diseases; and had hepatic cirrhosis. Eighty-six patients completed this study. CHB, chronic hepatitis
B; HBeAg, hepatitis B e antigen; HBeAg+/−, HBeAg positive/negative; LAM, lamivudine; LdT, telbivudine; M, months; MR, medical record; NUC,
nucleos(t)ide analog.
CMI Pan et al. Durability of CHB in LAM/LdT off therapy 1123.e3treatment after >24 months of consolidation therapy and were
followed up  48 months after treatment.
Laboratory measurements
Biochemical and liver function tests were performed manually
earlier in our study; automated systems were used routinely
later in the study when they became available at our clinical
laboratories. The serum ALT level of the ULN was set by the
laboratories at 50 U/L for both male and female patients. Serum
virologic markers, including HBsAg, anti-HBs, HBeAg, anti-HBe,
anti–hepatitis D virus and anti–hepatitis C virus were assayed
using the EIA kit (Abbott Diagnostics, North Chicago, IL, USA)
or as they were available. HBV genotype was determined using
PCR–restriction fragment length polymorphism of the surface
gene of HBV only after the year 2010. Serum HBV DNA was
detected applying the real-time ﬂuorescence quantitative PCR
assay with Tagman technique by using Biosystems ABI-7900
ﬂuorescence quantiﬁcation nucleic acid detector (ABI, Foster
City, CA, USA). Reagents kit was provided either by ABI Inc or
Zhejiang Biological Technology Co Ltd, Hangzhou; the lowest
limit of detection is 1 × 103 copies/mL. Serum HBsAg wasClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artiquantiﬁed using Roche Elecsys HBsAg II quant assay (minimum
fdetection limit, 0.05 IU/mL; Roche Diagnostics, Mannheim,
Germany) when it was accessible.
Statistical analysis
Statistical analysis was performed by SPSS 18.0 (IBM, Chicago,
IL, USA). Chi-square test and independent Student’s t test were
applied for the categorical and continuous variables, respec-
tively, between groups of patients with sustained response and
relapse. Continuous variables were described as mean or me-
dian (range). Cox regression model was used to predict the
factors related to clinical relapse. The Kaplan-Meier method
with log-rank test was used to calculate cumulative relapse
rates. A p value of two-tailed <0.05 was considered signiﬁcant.ResultsGeneral information
Among 368 CHB patients treated with LAM or LdT in our
clinics, 107 had discontinued therapy, including an exclusion ofropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 1. Baseline characteristics between chronic hepatitis B patients with relapse and sustained response
Characteristic Total (n [ 86) Sustained response (n [ 41) Relapse (n [ 41) p (n [ 45)
Age (years) 0.66
Median (range) 32.2 (18–57) 29.8 (18–51) 31 (20–57)
Mean ± SD 30.7 ± 2.5 28.6 ± 2.8 33.6 ± 2.6
Gender, n (% male) 67 (77.9%) 8 (56.7%) 29 (43.3%) 0.79
Genotypes (n = 41), n (%)
B 16 (39.0%) 7 (43.6%) 9 (56.4%) 0.55
C 20 (48.8%) 8 (40.0%) 12 (60.0%) 0.37
LAM/LdT 48/38 17/26 31/12
HBV DNA (log copies/mL)
Median (range) 7.21 (5.05–9.68) 5.72 (5.04–7.40) 8.68 (5.19–9.68) 0.06
<106 copies/mL 48 (55.8) 36 (87.8) 12 (26.7) 0.04
106 copies/mL 38 (44.2) 5 (12.2) 33 (73.3) 0.02
HBsAg (IU/mL)
Median (range) 8298 (105–98 745) 7696 (105–68 845) 8197 (450–98 745) 0.59
>100 IU/mL 13 (15.1%) 5 (12.2%) 7 (15.6%) 0.66
>500 IU/mL 26 (30.2%) 13 (31.7%) 12 (26.7%) 0.49
>1000 IU/mL 31 (36.0%) 16 (39.0%) 17 (37.8%) 0.85
>1500 IU/mL 16 (18.6%) 7 (17.1%) 9 (20.0%) 0.76
ALT (IU/L)
Median (range) 81.5 (23–347) 76 (45–346) 103 (23–347) 0.09
Mean ± SD 97.16 ± 8.45 95.03 ± 11.25 130.45 ± 18.22
Serum bilirubin (μmol/L), median (range) 31.8 (8.0–140.0) 31.8 (9.0–140.0) 4.0 (8.0–120.0) 0.82
LAM/LdT, lamivudine/telbivudine.
1123.e4 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIeight cases with <24 months’ consolidation therapy and 13
cases with a follow-up period of <48 months. Eighty-six patients
met the criteria for the study. Demographics of study patients
are presented in Fig. 1. The majority (77.9%) of patients were
male. The mean age was 32.2 years (range, 18–57 years). None
of the 86 patients showed clinical or histologic evidence of
cirrhosis at enrollment. Of the 86 patients, 56 were HBeAg
positive and 30 were HBeAg negative. Forty-one patients
completed assays for HBV genotype; 16 (51.2%) and 20 (48.8%)
were infected with genotypes B and C, respectively, and ﬁve
were undetermined; 45 of the remaining were in the earlier
cases and had no serum samples reserved. The average dura-
tions of LAM and LdT treatment were 43 ± 12 months and
32 ± 8 months and were followed by consolidation therapy for
averages of 29 ± 7 and 26 ± 8 months, respectively. The
baseline characteristics between the those who experienced
relapse and sustained response are shown in Table 1. There
were no signiﬁcant differences between the two groups during
the treatment and follow-up periods in age, gender, ALT or
total bilirubin, except that HBV DNA was lower in those with
sustained response (p 0.04).
Cumulative relapse rates
Of the 86 patients, 45 (52.3%) experienced relapse during the
post-treatment, continuous follow-up of up to 122 months. The
median follow-up duration was 115 months (range, 48–122
months). The relapse rate in the ﬁrst year was 51.1% during a
median follow-up of 108 months; adding the second year, the
relapse rate became 77.8% during a median follow-up of 98
months. The number of those who experienced relapse was
mostly distributed in the ﬁrst 48 months, which included 93.3%Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceof those with total relapse. Only 6.7% of those who experi-
enced relapse were scattered in the remaining 6 to 7 years
(Fig. 2). The relapse rates in HBeAg-positive and HBeAg-
negative patients were 39.3% and 76.7% with an average
follow-up of 96 months and 116 months, respectively (p 0.002).
The relapse rate in HBeAg-positive patients was signiﬁcantly
lower than that in HBeAg-negative patients.
Factors relevant to relapse
The characteristics at baseline and on-treatment of patients
with or without clinical relapse are compared in Tables 1 and 2.
In univariate analysis, all the baseline characteristics were
comparable between those who experienced relapse and those
who experienced sustained response except for a higher HBV
DNA in those with relapse: 8.68 (range, 5.19–9.68 log copies/
mL) versus 5.72 copies/mL (range, 5.04–7.40 log copies/mL) (p
0.04). Comparison of the on-treatment factors between relapse
and sustained response in HBeAg-positive and HBeAg-negative
patients showed that there was no signiﬁcant difference in
treatment duration and consolidation therapy duration; treat-
ment time was a little longer in HBeAg-negative patients.
HBsAg levels at off-therapy in those with sustained response of
the HBeAg-positive and HBeAg-negative patients were lower
than those in the patients with relapse. More patients obtained
EVR in sustained response than in relapse (p < 0.01), indicating
that early rapid suppression of HBV replication might be closely
related to later relapse in a long-term follow-up period
(Table 2).
In a multivariate analysis with Cox proportional hazard
regression model, the signiﬁcant risk factors of relapse were
HBV DNA level at baseline and HBsAg level at end of therapyropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
nses/by-nc-nd/4.0/)
Follow-up period (months)     12                24                36               48                 60                72              122
Relapsers In HBeAg+              13                  5                  1                 2                    0                  0                   0



















FIG. 2. Distribution of patients who
experienced relapse in HBeAg-positive
and HBeAg-negative patients for 122-
month follow-up. Total of 52.3% of
CHB patients experienced relapse.
Number of patients who experienced
relapse was mostly distributed in the ﬁrst
48 months (93.3% of total). Only 6.7% of
those who experienced relapse experi-
enced it during last 6 to 7 years. Rates of
relapse in HBeAg-positive and HBeAg-
negative patients are different. CHB,
chronic hepatitis B; HBeAg, hepatitis B e
antigen; HBeAg+/−, HBeAg positive/
negative.
TABLE 2. Comparison of on-treatment factors associated with relapses between those who experienced relapse and those who
experienced sustained response in HBeAg+/− chronic hepatitis B patients
On-treatment factor Total (n [ 86) Sustained response (n [ 41) Relapse (n [ 45) p
Treatment duration (months), mean ± SD 25 ± 3 22 ± 2 28 ± 2 0.48
HBeAg+ 24 ± 2 22 ± 2 26 ± 2 0.51
HBeAg− 31 ± 6 26 ± 5 38 ± 3 0.19
Consolidation therapy (months), mean ± SD 26.2 ± 3 25.8 ± 4 26.4 ± 2.3 0.48
HBeAg+ 26 ± 3 25.2 ± 2 26.1 ± 4 0.59
HBeAg− 26.8 ± 4 26.2 ± 2 27.1 ± 3 0.62
HBsAg at end of treatment (IU/mL), mean ± SD 963 ± 216 639 ± 242 1311 ± 426 0.01
HBeAg+ 767 ± 149 556 ± 132 1121 ± 223 0.02
HBeAg− 865 ± 215 812 ± 219 1226 ± 209 0.04
Virologic response (6 months), n (%)
HBV DNA reduction >2log 19 (22.1) 14 (34.1) 5 (11.1) 0.01
HBeAg+ 13 (15.1) 9 (22.1) 4 (8.9) 0.01
HBeAg− 6 (7.0) 4 (10.1) 2 (4.4) 0.02
HBV DNA negativity 13 (15.1) 9 (22.0) 4 (8.9) 0.01
HBeAg+ 8 (9.3) 7 (17.1) 1 (2.2) 0.01
HBeAg− 3 (3.5) 2 (4.9) 1 (2.2) 0.04
HBeAg, hepatitis B e antigen; HBV DNA negativity, HBV DNA <1 × 103 copies/mL.
CMI Pan et al. Durability of CHB in LAM/LdT off therapy 1123.e5(p 0.003, 0.04). Age, gender, serum bilirubin level, ALT level,
genotype and duration of treatment were comparable
(Table 3).
The cumulative relapse rate in HBeAg-positive patients was




ALT level at baseline 0.016
Serum bilirubin at baseline 0.063
Genotype (B/C/unknown) −0.388
HBV DNA level at baseline −1.211
Treatment duration 0.008
HBsAg level at end of treatment 0.000
CI, conﬁdence interval; RR, relative risk; SE, standard error.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artiSubsequent analysis of antiviral effects on relapse showed that
the relapse rate in patients with EVR was 21.4%. This group of
patients with both lower baseline HBV DNA (<106 copies/mL)
and lower off-therapy HBsAg (<1.5 × 103 IU/mL) had a low
relapse rate of 10.7% (Fig. 3).ronic hepatitis B patients
SE RR (95% CI) p
0.018 1.032 (0.997–1.075) 0.067
0.421 1.068 (0.476–2.386) 0.887
0.038 1.012 (0.912–1.560) 0.058
0.088 0.932 (0.907–1.075) 0.067
0.267 0.683 (0.398–1.180) 0.173
0.328 0.298 (0.128–0.688) 0.003
0.010 0.995 (0.974–1.012) 0.454
0.000 1.000 (1.000–1.000) 0.041
ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 3. Relapse rates on combination of
relevant factors in HBeAg-positive pa-
tients. Total of 39.3% of relapse rates in
HBeAg-positive patients were within 122-
month (10.2-year) follow-up. Relapse
rates in patients with EVR were 21.4%.
Lowest relapse rates of 10.7% were
found in EVR patients with lower HBV
DNA (<1 × 106 copies/mL) at baseline
and lower HBsAg (<1.5 × 103 IU/mL) at
end of treatment. CHB, chronic hepatitis
B; EVR, early viral response; HBV, hepa-
titis B virus; M, months.
1123.e6 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIHBsAg seroconversion
Eight patients experienced HBsAg loss, and in six patients it was
followed by seroconversion during the on-treatment (LAM,
n = 2; LdT, n = 5) and the post-treatment (LdT, n = 1) with a
median follow-up period of 84 months (range, 38–122
months). None of these patients experienced relapse during
this follow-up period.
Signiﬁcant adverse events and retreatment
None of the LAM- and LdT-treated patients had documented
signiﬁcant adverse events except for four LdT-treated patients,
who experienced muscle aches and were found to have instant
elevation of creatine kinase but did not need to discontinue
therapy.DiscussionThe major ﬁndings of this study are that 52.3% of LAM- and
LdT-treated off-therapy CHB patients experienced relapse over
the 10-year follow-up period; the majority experienced relapse
within 4 years. The relapse rate in HBeAg-negative patients was
much higher than in HBeAg-positive patients (76.7% vs. 39.3%).
HBeAg-positive patients who experienced EVR and experi-
enced HBeAg loss and/or seroconversion had a low relapse
rate, particularly in patients with a lower level of baseline HBV
DNA (<106 copies/mL) and a lower level of HBsAg
(<1.5 × <103 IU/mL) at the end of therapy.
High relapse rates were found in CHB patients with LAM
and LdT off-therapy. NUCs therapy, regardless of differences in
antiviral potency and extent of genetic barrier to resistance, has
limited or even no effect on the level of intrahepatic covalently
closed circular HBV DNA (cccDNA) as a viral transcriptional
template [19]. Therefore, despite the application of a stringentClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceprotocol of therapy in non-cirrhotic NUC-naive CHB patients
in our study, a high rate of clinical relapses persisted. A total of
52.3% of the 86 patients experienced relapse during the follow-
up of 10 years. This high rate of relapse raises a question of the
feasibility for off-therapy in over half of the NUC-treated CHB
patients who may not be appropriate for discontinuation,
particularly in the HBeAg-negative patients. Therefore, an
important question that remains is whether NUCs treatment
can be discontinued in all of the CHB patients after a period of
virus suppression.
Currently updated international guidelines for the manage-
ment of CHB with antiviral therapy set different stopping rules
for HBeAg-positive and HBeAg-negative patients. Following the
guidelines, the ideal end point of therapy is HBsAg loss, but this
is often not attained with the current anti-HBV therapy. There
are two treatment strategies for CHB patients: interferon and
NUCs. A ﬁnite course of treatment with NUCs is considered
to be feasible in HBeAg-positive, noncirrhotic patients who
seroconvert to anti-HBe while on-treatment and have unde-
tectable serum HBV DNA. Once anti-HBe seroconversion
occurred, treatment should be maintained for an additional 6 to
12 months, according to the guidelines [1,9,10], to reduce re-
lapses. Long-term or indeﬁnite treatment with NUCs is rec-
ommended by American Association for the Study of Liver
Disease and European Association for the Study of the Liver
guidelines in HBeAg-positive patients with cirrhosis, even after
HBeAg seroconversion, and HBeAg-negative patients unless
HBsAg loss and/or seroconversion occurs [1]. On the other
hand, both Asian Paciﬁc Association for the Study of the Liver
and the CMA guidelines suggest that discontinuation could be
considered in HBeAg-negative patients if the patients have been
treated for at least 2 to 2.5 years and undetectable HBV DNA
has been documented on three separate occasions 6 months
apart [10,18]. In our study, we stringently followed the stoppingropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
nses/by-nc-nd/4.0/)
CMI Pan et al. Durability of CHB in LAM/LdT off therapy 1123.e7rule of the CMA guidelines and found a high relapse rate in a
follow-up of 10 years, especially in HBeAg-negative patients,
which supports the recommended guidelines that NUCs ther-
apy in HBeAg-negative CHB patients should be continued until
the recognized treatment end point of HBsAg seroclearance.
In addition to having a high relapse rate, this long-term
observational study further extends our understanding on the
pattern of relapses and speciﬁes the proportions of those who
experience relapse, who are mostly clustered during the ﬁrst 4
years, which is as high as 93.3% of total relapse. Only 6.7% of
those who experience relapse remain in the last 6- to 7-year
follow-up period (Fig. 2). This ﬁnding has a clinical signiﬁcance
in that if a patient could persist and adhere to therapy, reach an
indication for off-therapy and follow up for a ﬁnite duration of 4
years with close monitoring without relapse, he or she might be
expected to have a low relapse rate. This is very important to
patients who cannot bear a long-term or indeﬁnite therapy and
must stop NUCs therapy because of other complications,
ﬁnancial burden, drug availability, persistence and adherence or
development of drug resistance.
There are different relapse rates in HBeAg-positive and
HBeAg-negative patients treated with LAM or LdT after off-
therapy. Regardless of the difference in study population, results
that focused speciﬁcally on relapse rates of NUCs off-therapy
showed that the relapse rates in HBeAg-positive patients treated
with LAM or LdT were 44% to 53% during the follow-up of 48 to
60 months, and the relapse rates in HBeAg-negative patients
treated with LAM, LdT, adefovir, ETV and tenofovir were 23% to
91% during the follow-up of 12 to 60 months [11,20–23]. Data
reported on either HBeAg-positive or HBeAg-negative patients
with different NUCs and multi-therapeutic strategies have
shown a wide range of relapse rates, from 25 to >50% [11,12],
mostly with a follow-up period of 1 to 2 years, a short term
during which the fate of NUCs off-therapy could hardly be
determined. In this study, a much higher relapse rate in HBeAg-
negative patients (76.7%) was found during a long-term follow-up
period, which is similar to the results reported by Kim et al. [24].
This ﬁnding strongly supports the guidelines [1,9] of continuous
long-term therapy in HBeAg-negative patients, even in younger
patients without cirrhosis.
The ability to identify patients whowill not experience durable
virus suppression in response to a speciﬁc antiviral regimen
provides an opportunity for early treatment modiﬁcation to
optimize outcomes and avoid the development of antiviral resis-
tance, which is the road-map concept proposed [25]. Substantial
evidence demonstrates that on-treatment factors such as serum
HBVDNA,HBsAg, HBeAg levels, and HBeAg andHBsAg loss are
associated with SVR and the development of drug resistance. The
guidelines for treatment of CHB universally recommendClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artimonitoring serum HBV DNA levels at treatment weeks 12 and
24. The current study also provided evidence for continuous
monitoring of serum HBsAg levels in HBeAg-negative patients
who discontinue adefovir therapy [23]. There is now strong evi-
dence that the decline of bothHBVDNA andHBsAg, reﬂected by
EVR and HBsAg level at the end of treatment, are predictors of
SVR and a low relapse rate after off-therapy (p < 0.05). Data
showed that HBsAg levels >20 000 IU/mL or no decline in HBsAg
levels atweek 24 are associatedwith a very lowprobability of anti-
HBe seroconversion [26]. In patients who are HBeAg-negative,
HBVDNA reduction to <20 000 IU/mL at 12 weeks and a decline
in HBsAg of more than 10% at 24 weeks are associated with SVR
[9]. In contrast, no HBsAg decline and a decline in HBV DNA of
less than 2 log10 IU/mL at week 12 is predictive of no response
[27]. In our study, for both HBeAg-positive and HBeAg-negative
patients, HBV DNA decreased to an undetectable level (<103
copies/mL) at week 24, i.e. EVR, or HBV DNA reduction over 2
log10 IU/mL in 24 weeks, and a decline in HBsAg levels to below
1.5 × 103 IU/mL at off-therapywere strongly associatedwith a low
relapse rate. This approach may help identify appropriate candi-
dates for off-therapy from a large pool of CHB patients currently
receiving continuous anti-HBV therapy as a result of concerns
about the risk of ﬂare and decompensation of the liver function.
HBeAg seroconversion has been considered as a signiﬁcant
marker for subsequently successful treatment in HBeAg-positive
CHB [28,29], as it is associated with improved long-term out-
comes [4,24] and allows cessation of treatment in patients who
experience sustained response. Our data showed that the
relapse rate in HBeAg-positive patients who experienced HBeAg
loss followed by seroconversion is much lower than in their
HBeAg-negative counterparts; but even so, not all patients
maintained a SVR to the end of the study. One patient treated
with LAM who experienced HBeAg loss followed by serocon-
version did not relapse until 9.2 years after off-therapy. This
suggests that patients with HBeAg seroconversion and a long-
term sustained response still have a chance to have reactivated
viral replication, and continuous monitoring is necessary.
In most instances, HBsAg loss followed by seroconversion is
uncommon in NUC-treated patients. A recent study showed
that serial HBsAg quantitation is a useful predictor of sero-
conversion in patients treated with peginterferon [30]. HBsAg
levels are thought to be related to cccDNA in hepatocytes.
Eight patients (9.3%) in our study experienced HBsAg loss and
seroconversion during on treatment and off-therapy; no relapse
occurred in these patients during follow-up, supporting HBsAg
loss seroconversion as a solid indicator for off-therapy. This
HBsAg seroconversion rate is similar to that reported in natural
seroconversion (1.2% annually) [9], implying that the rate of
HBsAg seroconversion is not signiﬁcantly affected by differentropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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cally monitor HBsAg quantity; additional studies with serial
monitoring of HBsAg are warranted.
Limitations
This study has some limitations. Firstly, our study only included
patients who had long-term follow-up data, who had no prior
treatment with NUCs and who stringently met the indication
for off-therapy. Therefore, the size of the eligible study popu-
lation was smaller, especially for HBeAg-negative patients, to
obtain sufﬁcient information, which might inﬂuence the results
explanation. Secondly, we evaluated the relapse rates of NUCs
with a low barrier to resistance, mild to moderate potency in a
partially prospective study with no comparison of durability
with other ﬁrst-line agents. However, the pattern of relapse for
the ﬁrst and second year in our data was similar to the pattern
of relapse studied with ETV [16], suggesting that NUCs for the
treatment of CHB share a common characteristic of relapses.
Conclusions
Long-term follow-up of NUC-naive CHB patients with LdT or
LAM off-therapy demonstrated that half of the patients experi-
enced relapse. Most relapses occurred within the ﬁrst 4 years,
during which follow-up is critical for off-therapy patients. The
lowest relapse rate was found in HBeAg-positive patients who
experienced EVR and who had lower HBV DNA as well as lower
HBsAg. HBsAg seroconversion was a solid indicator for SVR.
Therefore, clinical practice of NUCs off-therapy should likely
include continuous monitoring of HBVDNA andALT. The results
from this long-term study are of clinical signiﬁcance as they sup-
port determining appropriate treatment options, identifying can-
didates of priority for withdrawal of antiviral and optimizing
individual treatment strategies based on factors relevant to
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grant support. Supported in part by research funds from local
government, Hangzhou City Science and Technology Bureau
(2010, 20100733Q15, Zhejiang, China). All authors report no
conﬂicts of interest relevant to this article.AcknowledgementWe thank S. Taylor, University of California, San Francisco, for
her reviewing and editing work.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceReferences[1] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology
2009;50:661–2.
[2] McMahon B. The natural history of chronic hepatitis B virus infection.
Hepatology 2009;49:S45–55.
[3] Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcomes of
patients with chronic hepatitis B who do not meet criteria for antiviral
treatment at presentation. Clin Gastroenterol Hepatol 2015;13:
193–201.
[4] Chang TT, Lai YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term
entecavir therapy results in the reversal of ﬁbrosis/cirrhosis and
continued histological improvement in patients with chronic hepatitis
B. Hepatology 2010;52:886–93.
[5] Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al.
Regression of cirrhosis during treatment with tenofovir disoproxil
fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Lancet 2013;381:468–75.
[6] Liaw YF. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral
therapy. J Hepatol 2013;59:880–1.
[7] Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J,
Lau G, et al. Persistence of cccDNA during the natural history of
chronic hepatitis B and decline during adefovir dipivoxil therapy.
Gastroenterology 2004;126:1750–8.
[8] Bourne EJ, Dienstag JL, Lopez VA, Sander TJ, Longlet JM, Hall JG, et al.
Quantitative analysis of HBV cccDNA from clinical specimens: cor-
relation with clinical and virological response during antiviral therapy.
J Viral Hepat 2007;14:55–63.
[9] European Association for the study of the Liver. EASL clinical practice
guidelines: Management of chronic hepatitis B virus infection. J Hepatol
2012;57:167–85.
[10] Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al.
Asian-Paciﬁc consensus statement on the management of chronic
hepatitis B: a 2012 update. Hepatol Int 2012;6:531–61.
[11] Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. High prevalence of
late relapse and reinfection in prisoners treated for chronic hepatitis
C. J Gastroenterol Hepatol 2010;25:1276–80.
[12] Byun KS, Kwon OS, Kim JH, Yim HJ, Chang YJ, Kim JY, et al. Factors
related to post-treatment relapse in chronic hepatitis B patients who
lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol 2005;20:
1838–42.
[13] Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA,
et al. Reduced risk of relapse after long-term nucleos(t)ide analogue
consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther
2015;41:867–76.
[14] Khokhar N. Late relapse in chronic hepatitis C after sustained viral
response to interferon and ribavirin. J Gastroenterol Hepatol 2004;19:
471–2.
[15] Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, et al. Predictors of
relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
Aliment Pharmacol Ther 2011;34:344–52.
[16] Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, et al. Off
therapy durability of response to Entecavir therapy in hepatitis B e
antigen negative chronic hepatitis B patients. Hepatology 2013;58:
1888–96.
[17] Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, et al.
Treatment cessation of entecavir in Asian patients with hepatitis B e
antigen negative chronic hepatitis B: a multicentre prospective study.
Gut 2015;64:667–72.
[18] CMA. Chinese clinical practice guidelines for the management of
chronic hepatitis B. Chin J Hepatol 2011;3:40–56.
[19] Wong DKSW, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of
hepatitis B surface antigen and covalently closed circular DNA byropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
nses/by-nc-nd/4.0/)
CMI Pan et al. Durability of CHB in LAM/LdT off therapy 1123.e9nucleos(t)ide analogues of different potency. Clin Gastroenterol
Hepatol 2013;11. 1004–1010.
[20] Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, et al.
Virological and biochemical relapse after discontinuation of lamivudine
monotherapy for chronic hepatitis B in Japan: comparison with
breakthrough hepatitis during long-term treatment. Intervirology
2005;48:174–82.
[21] Barbon V, Gaia S, Marzano A, Lagget M, Rizzetto M. Prompt relapse of
viremia after lamivudine discontinuation in e-minus chronic hepatitis B
patients completely responders during 5 years of therapy. J Hepatol
2004;41:500–1.
[22] Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H,
Weegink CJ, et al. Reduction of relapse rates by 18-month treatment
in chronic hepatitis C. A Benelux randomized trial in 300 patients.
J Hepatol 2004;40:689–95.
[23] Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E.
Sustained responses and loss of HBsAg in HBeAg-negative patients
with chronic hepatitis B who stop long-term treatment with adefovir.
Gastroenterology 2012;143. 629–636.e1.
[24] Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, et al. Durability
after discontinuation of nucleos(t)ide therapy in chronic HBeAg
negative hepatitis patients. Clin Mol Hepatol 2013;19:300–4.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access arti[25] Keeffe E, Zeuzem S, Koff R, Dieterich D, Esteban-Mur R, Gane EJ, et al.
Report of an international workshop: roadmap for management of
patients receiving oral therapy for chronic hepatitis B. Clin Gastro-
enterol Hepatol 2007;5:890–7.
[26] Pol AV-PaS. Hepatitis B virus treatment beyond theguidelines: special
populations and consideration of treatment withdrawal. Ther Adv
Gastroenterol 2014;7:148–55.
[27] Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F,
Cakaloglu Y, et al. Validation of a stopping rule at week 12 using HBsAg
and HBV DNA for HBeAg-negative patients treated with peginterferon
alfa-2a. J Hepatol 2012;56:1006–11.
[28] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:
507–39.
[29] Papatheodoridis GV, Manolakopoulos S, Dusheiko G,
Archimandritis AJ. Therapeutic strategies in the management of pa-
tients with chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:
167–78.
[30] Chan HL, Wong VW, Wong GL, Chim AM, Chan HY, Sung JJ. Early
hepatitis B virus DNA suppression can predict virologic response to
peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol
2008;6:1022–6.ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 1123.e1–1123.e9
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
